Tricida (TCDA) Rating Reiterated by Cowen

Tricida (NASDAQ:TCDA)‘s stock had its “buy” rating reaffirmed by equities researchers at Cowen in a note issued to investors on Friday.

Other research analysts have also recently issued research reports about the stock. Goldman Sachs Group initiated coverage on shares of Tricida in a research report on Monday, July 23rd. They set a “neutral” rating and a $32.00 price objective on the stock. Zacks Investment Research cut shares of Tricida from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Finally, JPMorgan Chase & Co. started coverage on shares of Tricida in a report on Monday, July 23rd. They set a “neutral” rating and a $34.00 target price on the stock.

Tricida stock opened at $28.41 on Friday. Tricida has a 52-week low of $21.87 and a 52-week high of $40.10.

Tricida (NASDAQ:TCDA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.19. Research analysts forecast that Tricida will post -3.12 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA purchased a new stake in shares of Tricida during the second quarter valued at about $6,016,000. TD Asset Management Inc. purchased a new stake in shares of Tricida during the second quarter valued at about $574,000. Jennison Associates LLC purchased a new stake in shares of Tricida during the second quarter valued at about $16,664,000. Dean Capital Investments Management LLC purchased a new stake in shares of Tricida during the second quarter valued at about $690,000. Finally, BlackRock Inc. purchased a new stake in shares of Tricida during the second quarter valued at about $9,498,000. Institutional investors own 62.43% of the company’s stock.

Tricida Company Profile

Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.

Featured Article: How to Invest in an Index Fund

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply